胆囊癌市场（2026—2031）
胆囊癌市场规模预计由2026年的30.1亿美元增至2031年的39.9亿美元，预测期复合年增长率为5.75%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
胆囊癌市场规模预计由2026年的30.1亿美元增至2031年的39.9亿美元，预测期复合年增长率为5.75%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.75% | 机构预测 |
| 市场规模 | 2026 | USD 3.01 billion | 机构预测 |
| 市场规模 | 2031 | USD 3.99 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| cancer_type | adenocarcinoma | 2025 | 86.240% |
| distribution_channel | hospital pharmacies | 2025 | 68.140% |
| geography | North America | 2025 | 40.610% |
| modality | treatment | 2025 | 75.310% |
| stage | Stage IV disease | 2025 | 55.140% |
关键结论
- cancer_type 维度中，adenocarcinoma 在 2025 年的公开份额为 86.24%。
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 68.14%。
- geography 维度中，North America 在 2025 年的公开份额为 40.61%。
- modality 维度中，treatment 在 2025 年的公开份额为 75.31%。
- stage 维度中，Stage IV disease 在 2025 年的公开份额为 55.14%。
主要参与者
- Merck & Co., Inc.
- AstraZeneca plc
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Increasing Incidence in High-Burden Regions | +0.800% | APAC core, including India, China, and South Korea, and South America, including Chile, Bolivia, and Peru | Long term (≥ 4 years) |
| Adoption of Immunotherapy-Based First-Line Regimens | +1.200% | Global, led by North America, Europe, and East Asia | Short term (≤ 2 years) |
| Expansion of Biomarker-Driven Treatment | +1.000% | North America, Europe, Japan, and South Korea | Medium term (2-4 years) |
| Advances in Diagnostic Imaging and Molecular Testing | +0.700% | Global, with early gains in tertiary care markets in China and India | Medium term (2-4 years) |
| Growth of Multidisciplinary and Minimally Invasive Care | +0.500% | High-income markets in North America and Europe, expanding to APAC | Medium term (2-4 years) |
| Expansion of Gallbladder Cancer Clinical Trials in Asia | +0.600% | APAC core, including China, India, South Korea, and Japan | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Late-Stage Diagnosis and Limited Surgical Eligibility | -1.500% | Global, most acute in APAC and South America | Long term (≥ 4 years) |
| High Cost of Advanced Therapies and Genomic Testing | -1.200% | APAC, South America, and MEA, with moderate relevance in Southern and Eastern Europe | Medium term (2-4 years) |
| Limited Gallbladder Cancer-Specific Evidence for Targeted Therapies | -0.800% | Global | Medium term (2-4 years) |
| Unequal Access to Specialist Care and Biomarker Testing | -0.600% | Rural APAC, South America, and Sub-Saharan Africa | Long term (≥ 4 years) |
报告关注的关键问题
What is the projected value of the Gallbladder cancer market in 2031?
The Gallbladder cancer market is projected to reach USD 3.99 billion by 2031, from USD 3.01 billion in 2026, at a 5.75% CAGR.
Which gallbladder cancer treatment modality has the largest revenue share?
Treatment held 75.31% of revenue by modality in 2025 because advanced disease often requires multi-cycle systemic treatment.
Why is diagnosis growing faster than treatment in gallbladder cancer?
Diagnosis is projected to grow at a 7.25% CAGR as AI imaging, liquid biopsy, and genomic profiling gain wider use.
Which cancer type accounts for the largest share of care demand?
Adenocarcinoma accounted for 86.24% of the cancer-type share in 2025 and remains the core population for systemic treatment.
Which region is growing fastest for gallbladder cancer care?
Asia-Pacific is projected to grow at a 6.25% CAGR through 2031, supported by disease burden, trial activity, and expanding oncology infrastructure.
What limits access to newer gallbladder cancer therapies?
Late-stage diagnosis, uneven specialist access, reimbursement limits, and the cost of advanced medicines and genomic testing remain key constraints.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence